Recently, bi-functional molecules that can redirect immune effectors to tumour cells have emerged as potentially robust mediators of tumour regression in clinical trials. Two modalities in particular, bi-specific antibodies for T-cell redirection and activation (BiTe) and immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC), are being evaluated in efficacy studies as 'off-the-shelf' reagents. Optimal therapy will require an understanding and means to address regulatory mechanisms of limiting efficacy. In light of this, we evaluated the impact of induced regulatory T (iTreg) cells on the efficacy of tumour cell killing redirected by ImmTAC and demonstrated down-regulation of T-cell proliferation and expression of CD25, CD107a, Granzyme B and Perforin by ImmTACredirected T cells. Significant recovery of ImmTAC potency, however, could be achieved when combined with an anti-programmed cell death protein 1 monoclonal antibody. Furthermore, we found that among lung cancer patients failing to respond to ImmTAC therapy, there was a significantly higher fraction of Treg cells in the peripheral blood mononuclear cells of lung cancer patients than in healthy donors. These results provide in vitro evidence for an iTreg cell-mediated immunosuppression of ImmTAC-redirected T-cell responses. Whilst immune checkpoint blockade can reverse the Treg cell suppression, it forms a rational basis for a combination of the blockade with ImmTAC in clinical trials.
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Introduction
Immune-based therapy for cancer is emerging as an important treatment modality for patients for whom conventional therapy has failed. Although remarkable results have been observed for some cancers, tumour immune escape remains a challenge facing researchers and clinicians. 1 The contribution of tumour infiltrating lymphocytes, found in the tumour microenvironment (TME), in tumour control 2 may be mitigated by the presence of regulatory T (Treg) cells, which preferentially traffic to tumour sites. 3, 4 In animal models, selective Treg cell depletion can enhance immunotherapeutic strategies, 5 and clinical studies have suggested poorer prognosis in patients with elevated Treg cell levels. 6, 7 Two types of Treg cells have been identified: 'natural' Treg (nTreg) cells, 8 which develop in thymus, and 'induced' Treg (iTreg) cells, which can arise in the periphery from conventional T cells in the TME via tumour-derived signals, including transforming growth factor-b (TGFb). [9] [10] [11] Epigenetic differences between these two types of Treg cells have shown that nTreg cells are associated with stable forkhead box P3 (Foxp3) expression and wider demethylation patterns compared with iTreg cells. 12 Although, the contribution of nTreg versus iTreg cells in maintaining tolerance as well as tumour escape from the TME is not completely understood, [13] [14] [15] circulating Treg cells in healthy donors are largely represented by nTreg cells, whereas iTreg cells seem to play a key role in the TME in suppressing the antitumour immune response. 14, 16 With respect to tumour tolerance in the TME, augmenting tumour-specific cytotoxic T lymphocyte (CTL) response strategies may be negatively affected by the increased numbers of iTreg cells. In addition, tumours will down-regulate the expression of major histocompatibility complexes (MHCs) to evade immune scrutiny, which will present a huge challenge to the T cells with naturally expressing low-affinity antigen receptors to complete the immune tasks. 17 To overcome the problem of the natural immune-synapse formed with low-affinity interactions, affinity-enhanced T-cell receptors (TCRs) are designed. 18 On the other hand, to harness a patient's own CTLs, an immune-mobilizing monoclonal TCR against cancer (ImmTAC) was constructed to hold two ends: one with a high-affinity TCR to engage the tumour antigenderived peptide-MHC complex on the target cells and the other, a humanized anti-CD3 scFv (single-chain variable fragment) to recruit CTLs. The fusion molecule may form a central molecular complex that establishes an artificial immune-synapse for activating CD3 + T cells in the proximity of tumour cells in the TME. [18] [19] [20] Such a highaffinity TCR-made immune-synapse will allow CTLs to express essential molecules, such as CD25, CD107a, Granzyme B and Perforin to complete the killing process. Expression of Foxp3 is required for iTreg cell development and appears to control a genetic programme specifying the cell fate. 25 Although the PD-1/PD-L1 pathway drives the differentiation and maintenance of Foxp3 + Treg cells by blocking the Akt/mammalian target of rapamycin pathway, PD-1 deficiency impairs the expression of FoxP3 in iTreg cells in vivo. 26 These results demonstrated that PD-1/PD-L1 signalling has a vital role in iTreg cell development and sustaining iTreg cell function. Blockade of the PD-1/PD-L1 pathway using anti-PD-1 or anti-PD-L1 antibodies reverses the suppressive ability of iTreg cells. 27 In this study, we first examined whether iTreg cells posed a significant barrier to the antitumour effect of ImmTAC-redirected CD8 + T cells and second whether a treatment in combination with anti-PD-1 antibody could reverse iTreg cell-mediated immunosuppression of ImmTAC. We further examined this question using samples of peripheral blood from lung cancer patients. The observation can be used as a rationale for embarking on clinical studies combining ImmTAC and immune checkpoint blockade regimens.
Materials and methods

Cell preparation and culture
We enrolled 29 patients with lung cancer in the First Affiliated Hospital of Guangzhou Medical University and 29 healthy donors. The NCI-H1299 non-small cell lung cancer cells (HLA-A*0201, HLA-A*2402, NY-ESO-1 positive determined with nanostring) were a gift from XiangXue Life Sciences Research Centre (XiangXue Pharmaceutical Co. Ltd, Guangzhou, China), and cultured with RPMI-1640 medium supplemented with 10% fetal bovine serum. We verified the antigen expression and HLA restriction of the cell strain using Western blotting and fluorescence-activated cell sorting (FACS) (see Supplementary material, Fig. S1 ). The T2 cells and the T cells were cultured with Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum. These cells were all free from mycoplasma detected by polymerase chain reaction every month.
FACS analysis
The cells were washed once with FACS staining buffer and then stained for 30 min at 4°with antibodies specific for human CD4-fluorescein isothiocyanate (Clone: RPA-T4, Cat: 
Induction of human iTreg cells in vitro
The stimulation of CD4 + CD45RA + CD25 À T cells with human T-activation anti-CD3/CD28 beads (Dynabeads, Cat: 11131D; Gibco, ThermoFisher, Waltham, MA) at a cell to bead ratio of 3 : 1 was carried out by culturing in 24-well plates with AIM medium which was supplemented with IL-2 (400 U/ml, R&D Systems, Minneapolis, MN), TGF-b 1 (25 ng/ml, R&D) and rapamycin (400 ng/ml, R&D). This cytokine cocktail was referred to as an 'induction cocktail' (IC) and the concentration of the CD4 + CD45RA + CD25 À T cells was 2 million/ml at the beginning of the induction assay. The activated CD4 + T-cell control culture was set similarly with the same concentration of anti-CD3/CD28 beads and 100 U/ml IL-2. At day 5, cells were harvested for FACS analysis to detect the expression of FoxP3, or carried on for further experiments.
Enzyme-linked immunosorbent assay
The iTreg cells were cultured with AIM medium for 2 days, supernatants were collected to detect TGF-b 1 level using an enzyme-linked immunosorbent assay (ELISA) Kit (Cat: DKW12-1710-096; Dakewe, Guangdong, China). All protocols were conducted according to the manufacturer's instructions.
In vitro suppression assay
The carboxyfluorescein succinimidyl ester (CFSE; Cat: V12883; Invitrogen, Carlsbad, CA) -based suppression assay was performed as described previously. 28 Briefly, CFSE-labelled autologous peripheral blood mononuclear cells (PBMCs) were stimulated with anti-CD3/CD28 monoclonal antibody (mAb) beads at a cell to bead ratio of 3 : 1 and incubated with iTreg/CD4 + T cells at a ratio of PBMCs to iTreg/CD4 + T-cells of 4 : 1. For the proliferation assays redirected by ImmTAC-NYE, the CFSElabelled autologous PBMCs were cultured with iTreg/ CD4 + T cells at a PBMC to iTreg/CD4 + T-cell ratio of 2 : 1 in the presence of tumour cells and ImmTAC-NYE. After 3 days, these cells were harvested and stained with allophycocyanin-conjugated anti-CD8 antibodies to analyse the proliferation of CD8 + T cells by FACS.
28,29
Transwell and co-culture assays
Transwell experiment was performed in 96-well plates with 0Á4-lm pore sizes in inner wells (Cat: 3381; Corning, Corning, NY) to physically separate iTreg cells and the co-culture of PBMCs with NCI-H1299 cells in the presence of ImmTAC-NYE (1 9 10 À9 M). The co-cultures of PBMCs (1 9 10 5 ) with NCI-H1299 cells (2 9 10 4 ) were grown in 175 ll RPMI-1640 medium containing 10% fetal bovine serum using the outer wells. A total of 1 9 10 5 iTreg cells was added into the inner wells in 50 ll of the same medium and the plates were incubated for 48 hr. Then the co-cultures of PBMCs with NCI-H1299 cells were collected for detection of the expression of CD107a. This co-culture experiment was performed in 96-well round plates containing the iTreg cells (1 9 10 5 ) cultured together with PBMCs (1 9 10 5 ) and NCI-H1299 cells (2 9 10 4 ) for 48 hr in the presence of ImmTAC-NYE (1 9 10 À9 M). These cells from the co-culture system were collected for detection of the expression of CD107a.
Cytotoxic T lymphocyte assays
The CytoTox96 Non-Radioactive Cytotoxicity Assay kit (Cat: G1782, Promega, Madison, WI) was used to determine the CTL activity of PBMCs. In brief, triplicate wells containing 1 completed following the manufacturer's instructions, and results were calculated with the formula: Cytotoxicity = (Experimental -Effector Spontaneous -Target Spontaneous)/(Target Maximum -Target Spontaneous) 9 100%.
Statistical analysis
All graphics and statistical analyses were performed using GRAPHPAD PRISM 5 (GraphPad, San Diego, CA). Unpaired two-tailed t-tests were performed using the Student's t-test; Significances are indicated as *P < 0Á05, **P < 0Á01, ***P < 0Á001, and NS, P > 0Á05. Data are representative of at least three independent experiments and are means AE SEM.
Results
Induction and characterization of human iTreg cells
To + T cells. We verified the induction efficiency on 10 isolated healthy naive CD4 + T-cell samples. The iTreg populations were detected as 78Á7% on average (range 67Á3-90Á5%) expressing FoxP3 on day 5 with IC, which was significantly higher than the 19Á98% (range 14Á1-26Á7%) for control cells stimulated only by the anti-CD3/CD28 beads without the IC (Fig. 1b) .
To analyse the suppressive phenotype of the cells, intracellular IL-10 was measured. Results showed that an average of 39Á3% of cells produced IL-10 in the iTreg cell population, which was over 10-fold higher than the control cells (Fig. 1c) . Similarly, we detected TGF-b 1 levels in the culture supernatant by ELISA after the cells were cultured with AIM medium for 2 days. The results showed that amounts of TGF-b 1 secreted from the iTreg population were significantly higher than from the control cells (Fig. 1d) . We analysed the expression of Treg cell-related immunosuppressive cell markers by FACS, [30] [31] [32] [33] and found that the iTreg populations expressing GITR, PD-1, CTLA-4 and FoxP3 were 86Á5%, 98Á9%, 99Á7% and 88Á9%, respectively (Fig. 1e) . The negative control was
and results showed significantly lower expression levels for all these markers. Finally, the functional suppressive capacity of the iTreg cells was analysed using an in vitro proliferation assay, in which CFSE-labelled autologous PBMCs stimulated with anti-CD3/CD28 mAb beads were cultured with iTreg cells or activated CD4 + T cells without the IC induction at cell to PBMC ratios of 1 : 4. The viability of iTreg cells and control CD4 + T cells were similar as detected by FACS (see Supplementary material, Fig. S3 ). The fraction of proliferating cells among stimulation of CD8 + T cells was 37Á50%, whereas cultures exposed to the iTreg cells yielded a proliferating population of only 13Á80%, but in the control CD4 + T cells yielded 29Á80% proliferation (Fig. 1f) . Hence, the iTreg cells had an obviously superior suppressive capability in comparison to activated CD4 + T cells.
iTreg cells suppressed CTL killing redirected by ImmTAC-NYE
In this study, we refolded and purified the ImmTAC construct using previously generated high-affinity TCR (KD = 26 pM) specific for the HLA-A*0201 restricted epitope of NY-ESO-1 157-165 , 18 and named as ImmTAC-NYE. We demonstrated that the ImmTAC-NYE could redirect effector cells specifically to release interferon-c Fig. S4C,D) .
To evaluate the suppressive capacity of the iTreg cells, we examined the ability of in vitro induced iTreg cells to suppress ImmTAC-NYE-redirected target killing of NCI-H1299 cells or NY-ESO-1 peptide pulsed T2 cells. First, iTreg cells and activated CD4 + T cells without induction were added at the ratios of testing cell : PBMC of 1 : 2 to the co-culture system containing PBMCs and target cells in the presence of ImmTAC-NYE. The specific lysis results showed that activated CD4 + T cells without IC induction did not inhibit the lysis of NCI-H1299 cells and NY-ESO-1 157-165 -pulsed T2 cells. However, iTreg cells did inhibit the ImmTAC-NYE-redirected killing significantly in comparison to that of the activated CD4 + T cells (Fig. 2a,b) . The supplement of the activated CD4 + T cells might in fact promote the target cell lysis for both the peptide loaded T2 and NCI-H1299 cells, although without significance. Further investigation about the inhibition of ImmTAC-NYE redirected killing was also carried out with a range of different iTreg cells to PBMC ratios from 4 : 1 to 1 : 64. Results showed that even with the iTreg to PBMC ratio set to 1 : 64, suppression of ImmTAC-NYE-redirected killing could also be observed (see Supplementary material, Fig. S5 ).
Assays of CTLs were performed in the presence or absence of iTreg cells with ImmTAC-NYE concentrations ranging from 10 À8 M to 10 À13 M and a 1 : 2 ratio of iTreg cells to PBMCs. Interestingly, the iTreg cells could inhibit ImmTAC-NYE-redirected killing of NCI-H1299 cells and NY-ESO-1 157-165 -pulsed T2 cells at all concentrations of ImmTAC-NYE used in these assays (Fig. 2c,d) . The values of lysis EC 50 were increased in the presence of iTreg cells from 3Á951 9 10 À11 to 1Á953 9 10 À10 for the T2 cells, and 1Á856 9 10 À11 to 1Á179 9 10 À10 for the NCI-H1299 cells.
Finally, to further demonstrate the iTreg cell suppressive function against tumour cell killing, we verified cleaved caspase-3 expression by NCI-H1299 cells in ImmTAC-NYE-redirected CTL assays using an iTreg to PBMC ratio of 1 : 2. Activated CD4 + T cells without the IC-induction were used as a control. The NCI-H1299 cells were stained for verifying the true source of cleaved caspase-3 by gating the CFSE-positive cells. The result showed that the iTreg cells, but not the activated CD4 + T cells without the IC-induction were able to inhibit the expression of cleaved caspase-3 of the NCI-H1299 cells (Fig. 2e) .
Mechanisms by which iTreg cells suppressed ImmTAC-NYE-redirected CTL killing
To unveil the mechanism whereby the iTreg cells suppressing the function of ImmTAC-NYE redirected T cells, the CD8 + T-cell proliferation was studied. We added the ImmTAC-NYE to cell mixtures of CFSE-labelled PBMCs (effector) and NCI-H1299 cells (target) at a ratio of 5 : 1 and cultured them for 3 days with or without the autologous iTreg cells at a testing cell to PBMC ratio of 1 : 2. We analysed the CFSE dilution by gating CD8 + T cells. A separate control assay was set with the CD4 + T cells activated without the IC induction at the same ratio. The fraction of proliferating cells among ImmTAC-NYE-redirected CD8 + T cells was 93Á80%, whereas cultures exposed to iTreg cells yielded a proliferating population of only 3Á16%, cultures exposed to activated CD4 + T cells yielded a proliferating population of 24Á60% (Fig. 3a) . These data indicated significant iTreg cell suppressive effects on the ImmTAC-NYE redirected and activated CTL in the current conditions.
In addition, we investigated the effect of iTreg cells on the expression levels of several T-cell-activated and cytolytic markers. ImmTAC-NYE (10 À9 M) -redirected CTL assays were carried out by culturing for 24 hr at an effector : target ratio of 5 : 1 with or without the iTreg cells or the activated CD4 + T cells. These co-culture cells were collected and stained with the corresponding antibodies for analysis of the expression of CD25, CD107a, Granzyme B and Perforin by the CD8 + T effector cells. Results showed that the expression of CD25, CD107a, Granzyme B and Perforin were decreased significantly in the CD8 + T cells when treated with the iTreg cells, but not the activated CD4 + T cells without induction during the CTL assays (Fig. 3b,c) . By summarizing the result of three experiments, we could see a significant decrease in the expression of activated/cytolytic markers by CD8 + T cells with the presence of iTreg cells (see Supplementary material, Fig. S6 ). These results indicated that the iTreg cells suppressed the proliferation, activation and cytolytic functions of the T cells.
Anti-PD-1 mAb could reverse the suppressive effect of iTreg cells on ImmTAC-NYE-redirected cell killing
To investigate the relation between the iTreg cell function and the PD-1 axis, we assessed the effect of blocking the PD-1 pathway on both the iTreg cell conversion and the suppression of the ImmTAC-NYE-redirected CTL responses. First, we investigated whether the PD-1 blockade could reduce the conversion of the iTreg cells during the induction of CD45RA + CD4 + CD25 À T cells with the IC. We analysed the FoxP3 expression of the T cells after a 5-day induction with 10 lg/ml anti-PD-1 mAb added. The result showed that the conversion of the cells to CD4 + Foxp3 + iTreg cells was decreased by the addition of anti-PD-1 mAb (Fig. 4a) . Second, we analysed the FoxP3 expression in the iTreg cells cultured with the supplement of 10 lg/ml anti-PD-1 mAb for a further 2 days after the 5-day induction with just IC. In this case, we found that the addition of anti-PD-1 mAb could reduce the FoxP3 expression in already converted iTreg cells (Fig. 4b) , indicating that the stability of the iTreg cells could be reduced by the blockade of the PD-1 pathway. These results demonstrated that the anti-PD-1 mAb might potentially overturn the conversion and stability of iTreg cells in the immune-suppressive microenvironment.
Because cancer cells usually express high levels of PD-L1, they can efficiently trigger suppressive signals on activated T cells that normally up-regulate PD-1 surface expression. It is not surprising that 35Á0% of the cells in the lung cancer cell line of NCI-H1299 constitutively express PD-L1 (see Supplementary material, Fig. S7A ). Additionally, transwell assay showed that the iTreg cells exerted the suppressive ability mainly through cell-to-cell contact (Fig. 4c) , in comparison with the effector and iTreg cell co-culture assay, we observed no significant reduction of CD107a expression in the transwell assay, where the iTreg cells could not contact the effector cells. These data indicate that the cell-to-cell contact mechanism acting through the PD-1 pathway might play an important role in the suppressive activities. Therefore, we investigated whether PD-1 pathway blockade with the anti-PD-1 mAb could reverse the iTreg cell suppressive effects on killing NCI-H1299 cells by ImmTAC-NYEredirected T cells. The result showed that the ImmTAC-NYE combined with the anti-PD-1 mAb could enhance the CTL response to NCI-H1299 cells. Most importantly, the killing effect observed with the combination of I  II  III  IV   I  II  III  IV   I  II  III  IV   I  II  III  IV   I  II  III ImmTAC-NYE and anti-PD-1 mAb did not show significant reduction with the supplement of iTreg cells (Fig. 4d) . In comparison to ImmTAC-NYE with only iTreg cells added, the addition of anti-PD-1 mAb recovered over 81% of the tumour lysis by the redirected CD8 + T cells (or increased killing 1000-fold over the test with no PD-1 blockade). In addition, the CD25 expression of the CD8 + T cells increased significantly from 58Á3% to 81Á6% detected in the assays with the addition of the PD-1 blockade in the presence of iTreg cells (Fig. 4e) . By summarizing three experiment results, we could see a significant increase in CD25 expression of CD8 + T cells with the presence of anti-PD-1 mAb (see Supplementary material, Fig. S7B ). The data indicated that the PD-1 pathway blockade with anti-PD-1 mAb could recover the activation phenotype of CD8 + T cells.
Comparison of the killing by ImmTAC-NYEredirected CTLs between lung cancer patients and healthy donors
To determine whether PD1 blockade may have a role in combination with ImmTAC therapy, we collected PBMCs from 29 lung cancer patients and 29 healthy donors and evaluated the effectiveness of cancer cell killing by the ImmTAC-NYE-redirected T cells. The result of ImmTAC-NYE redirected lactate dehydrogenase release showed that the specific cancer cell lysis by the PBMCs was usually lower than that of healthy donors (Fig. 5a) , and the percentage of the CD4 + FoxP3 + Treg cells in these lung cancer patients' PBMCs was significantly higher than that in healthy donors (Fig. 5b) . Therefore, we wondered whether Treg cells were one of the dominant mechanisms for suppressing the ImmTAC-redirected CTL response in lung cancer patients.
Combination ImmTAC-NYE with anti-PD-1 mAb produced synergistic tumour cell killing in vitro for lung cancer patients
To better understand the mechanism of anti-PD-1 mAb overcoming the suppressive effects of the iTreg cells, we detected PD-1 expression levels on the PBMCs from lung cancer patients and healthy donors. We found that the PD-1 expression levels of CD4 + T cells from the patient group were up-regulated in comparison to the healthy donors (Fig. 6a) . When anti-PD-1 antibody was added to the CTL assay co-culture system, the enhancement of NCI-H1299 cell lysis in the lung cancer patient group was higher than in the healthy donors. Significantly, one patient sample showed that the PD-1 blockade enhanced the killing nearly eightfold in comparison to almost no change for a representative healthy control (Fig. 6b,c) .
Discussion
Three fundamental immunotherapeutic strategies are emerging as important anti-tumour approaches: (i) chimeric antibody receptor or TCR engineered T cells, 34, 35 (ii) bi-functional molecules such as BiTe, 36 ImmTAC 19 or HATac to redirect T cells to kill tumour cells, 37 and (iii) blocking immunosuppressive mechanisms using immune checkpoint reagents such as anti-PD-1, 38 anti-PD-L1 39 or anti-CTLA4 antibodies. 40 ImmTAC has been shown to redirect T cells to kill target tumour cells in vitro and in vivo with promising results. A previous study demonstrated that ImmTAC-gp100 could redirect and activate T cells to directly kill melanoma cells even in the presence of Treg cells; 41 however, the use of unstimulated nTreg cells in that study may have weak suppressive capacity. Our own studies confirmed that the use of unstimulated nTreg cells from healthy donors failed to demonstrate suppressive capability, but activated nTreg cells could mediate strong suppressive effects (unpublished data). The thymus-derived nTreg cells are responsible for peripheral tolerance in healthy individuals, and in pathological situations, nTreg cells are largely replaced by iTreg cells, which are the major participants in shaping the immune response in situ.
14 Therefore, iTreg cells can play a critical role in tumour immunosuppression. We used established in vitro methods to generate iTreg cells, which suppressed the activation and proliferation of ImmTAC-NYE-redirected T cells, and down-regulated the expression of CD25, CD107a, Granzyme B and Perforin. The results suggested that the strong immunosuppressive function of iTreg cells would become a hurdle for such immunotherapy.
In addition, it has been suggested recently that the expression of PD-1 on Treg cells contributed to the suppressive capability in vitro. 42 Studies have shown that PD-L1-immunoglobulin-coated beads could promote not only the development, but also the suppressive capacity of PD-1-expressing iTreg cells in vitro. 24 In vitro Treg cell suppression assays have suggested that PD-1 À/À Treg cells showed weakened suppression of the CD8 + T-cell proliferation and cytokine production. 43 Taken together, we postulated that inhibition of this immune checkpoint pathway may override the suppressive effect of iTreg cells on the ImmTAC-NYE redirected CTL response. The transwell assays in this study indicated that the iTreg cells wielded their suppressive effects through cell-to-cell contact, and co-cultivation of the ImmTAC-NYE-redirected CTL and iTreg cells in the presence of PD-1 blockade was able to reverse iTreg cell-mediated suppression of the response. As activated conventional T cells are known to express PD-L1, it may confirm that anti-PD-1 mAb blockades the interactions between PD-1-expressing iTreg cells and PD-L1-expressing conventional T cells, leading to the relief of immune tolerance built by the PD-1 axis. As the immune checkpoint protein PD-1 is also expressed on cytotoxic T cells, anti-PD-1 mAb may have a dual role Hence, we suspected that blockade of PD-1 signalling might restore Akt signalling, which assisted activation and proliferation of conventional CD4 + T cells rather than converting them into iTreg cells. In addition, the lack of PD-1 signalling in stimulated CD4 + T cells led to enhanced signal strength through the TCR, which was previously shown to inhibit iTreg cell generation in a nuclear factor-jB-dependent manner even in the presence of TGFb and IL-2. 44 This is another explanation for how the blockade of PD-1 axis with antibodies can enhance the ImmTAC-NYE-redirected CTL responses during the presence of iTreg cells. Therefore, blocking of the PD-1 pathway should down-regulate FoxP3 expression. This also suggests that PD-1 signalling may play a key role in TGF-b-induced Treg cell conversion, strengthening the evidence for a link between PD-1 and TGF-b signalling in iTreg cells.
Finally, we demonstrated that the use of ImmTAC-NYE-redirected CTLs from PBMCs of lung cancer patients yielded significantly lower lytic capacity than those from PBMCs from healthy donors. This might be attributable to the higher iTreg cell level in the lung cancer patients compared with the healthy donors. The PBMCs from both the lung cancer patients and the healthy donors (n = 29) and lung cancer patients (n = 29). P value was calculated using unpaired Student's t-test. Significance is indicated as *P < 0Á05, ***P < 0Á001. (b, c) The anti-PD-1 mAb enhanced the ImmTAC-NYE-redirected cell killing in lung cancer patients and healthy donors. The peripheral blood mononuclear cells (PBMCs) (1 9 10 5 /well) were cultured for 24 hr with NCI-H1299 (2 9 10 4 /well) cells at a 5 : 1 effector to target ratio in the presence of ImmTAC-NYE (10 À9 M) and anti-PD-1 mAb (10 lg/ml) was added or not. The co-culture system without ImmTAC-NYE was used as negative control. Lactate dehydrogenase release was detected for lung cancer patients (b) or healthy donors (c). Unpaired Student's t-test, **P < 0Á01, NS P > 0Á05. populations in the peripheral blood between healthy donors (n = 27) and lung cancer patients (n = 27). Unpaired two-tailed t-tests, *P < 0Á05, ***P < 0Á001. healthy donors demonstrated enhanced ImmTAC-NYEredirected T-cell activity with the presence of anti-PD-1 mAb in comparison without the antibody, but the extent of the enhancement was significantly greater for the lung cancer patients than for the healthy donors. As FoxP3 and PD-1 were all up-regulated in lung cancer patients, anti-PD-1 mAb was able to reverse the up-regulated iTreg cell-mediated suppression by blocking up-regulated PD-1 signalling and down-regulating FoxP3 expression. These results suggested that the combination of ImmTAC-NYE with anti-PD-1 mAb might produce a synergistic antitumour effect in lung cancer patients for breaking iTreg cell-mediated immunosuppression. Blockade of the PD-1/ PD-L1 pathway with checkpoint-specific antibodies in lung cancer patients might enhance anti-tumour T-cell responses not only through re-activation of effector T cells but also by preventing the suppression of iTreg cells. These findings are of particular importance for clinical studies combining the ImmTAC and immune checkpoint blockade regimens.
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